Phylo
Phylo provides Biomni Lab, an AI-native Integrated Biology Environment in which multi-agent AI workflows orchestrate 300+ biomedical databases, models, and tools to plan and execute end-to-end biomedical research for academic labs, biotech, top-20 pharma, and healthcare systems.
- Company typePrivate
- Founded2026
- HeadquartersSouth San Francisco, United States
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What Phylo does
Phylo, Inc. is a Stanford AI Lab spin-out that builds Biomni Lab, a cloud-hosted Integrated Biology Environment (IBE) in which multi-agent AI agents orchestrate 300+ biomedical databases, software systems, and analytical tools to plan and execute end-to-end biomedical research workflows. The platform is anchored by a proprietary reinforcement-learning agent (Biomni-R0) tailored to biomedicine and a proprietary biomedical knowledge graph that captures every analysis, hypothesis, and decision trace from user sessions. Each session runs in a sandboxed environment with dedicated CPU, autoscaling GPU, and HPC access for specialized bio-AI models (AlphaFold, OpenFold 3, Boltz-2, ESMC-6B/ESMFold2, Evo 2, RNAPro, CodonFM).
The company serves biomedical research labs in academia and biotech, biopharmaceutical R&D organizations, healthcare systems, and AI-for-biology developers. Adoption signals include 7,000+ research labs and 4,300+ organizations using the open-source Biomni project, 8,400 preview users including 18 of the world's top 20 pharmaceutical companies, and named deployments at Ginkgo Bioworks and Mount Sinai. Scientific advisors include Nobel Laureate Carolyn Bertozzi, CRISPR pioneer Feng Zhang, and computational biologist Fabian Theis.
Phylo monetizes through a freemium self-serve product (Free tier, $100/month Pro with an .edu discount, $100/seat/month Team) plus custom-priced Enterprise contracts that include white-glove onboarding, SSO/RBAC, and customer-hosted VPC deployment. Distribution combines a self-serve PLG funnel, direct enterprise sales, a strategic GTM partnership with ZS, and embedded technology integrations with NVIDIA BioNeMo, Boltz, Biohub, and licensed data providers (Consensus, COSMIC, Addgene, GeneCards). The company is privately held, headquartered in South San Francisco, California, and closed a $13.5M seed round in February 2026 co-led by Andreessen Horowitz and Menlo Ventures' Anthology Fund.
Phylo firmographics
Firmographics- Name
- Phylo
- Legal name
- Phylo, Inc.
- Website
- https://phylo.bio
- Company type
- Private
- Founded year
- 2026
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Phylo provides Biomni Lab, an AI-native Integrated Biology Environment in which multi-agent AI workflows orchestrate 300+ biomedical databases, models, and tools to plan and execute end-to-end biomedical research for academic labs, biotech, top-20 pharma, and healthcare systems.
- Ownership category
- akta.pro rank
Phylo industry classification
Industry- Product category
- AI Biomedical Research Platform
- NAICS
- Software Publishers (513210), Computer Systems Design and Related Services (5415)
- SIC
- Services-Prepackaged Software (7372), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industries
- Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D) (HLAGAJAC), Sample / Biorepository & Biobank Informatics (Chain-of-Custody) (HLAGAJAH)
Keywords
Where Phylo is headquartered
LocationHeadquarters
- HQ city
- South San Francisco
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Phylo business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales
Revenue model
- Free / Individual Tier: Free self-serve tier with private workspace, full data ownership, concurrent task support, and HPC CPU/GPU access. Currently positioned as a free research preview but designed as a permanent freemium entry point.
- Pro Subscription: Pro plan at $100/month ($50/month with .edu email) for individual researchers, with 10x daily usage vs Free, more concurrent tasks, more compute, priority HPC access, and 7-day free trial. Recurring monthly billing with cancel anytime.
- Team Subscription: Team plan at $100/seat/month (discounted from $120) for startups and academic labs, with centralized admin workspace and billing, admin controls, and team collaboration features. Per-seat recurring subscription.
- Enterprise Contracts: Enterprise tier with custom pricing for large organizations, including custom agent development, internal data and tool integrations, unlimited daily usage, expandable compute and storage, flexible deployment (multi-tenant, single-tenant, or customer-hosted VPC), SSO, RBAC, white-glove onboarding, and enterprise-grade encryption. Includes professional services for custom integrations.
- Licensed Materials & Data Monetization (partnership/embedded fees): Phylo licenses proprietary third-party data and materials (e.g., Consensus for academic literature, COSMIC for cancer genomics, Addgene for plasmid discovery) and embeds them in Biomni Lab, granting end users limited sub-licensed access. Enterprise customers can pay for proprietary data and tool integrations.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | Pay-as-you-go | Individual Free — full-featured free plan for exploring Biomni Lab |
| Subscription | Monthly | Pro — paid plan for individual researchers |
| Per seat | Monthly | Team — for startups and academic labs |
| Other | Annual | Enterprise — custom for large organizations |
Go-to-market motion5 records
Distribution channels5 records
Marketing channels10 records
Phylo product offering
Product offeringCore offering
Phylo provides Biomni Lab, the first Integrated Biology Environment (IBE) — a unified cloud workspace where biologists collaborate with multi-agent AI to plan, execute, and review biomedical research end-to-end. The platform orchestrates 300+ biomedical databases, software systems, and analytical tools within sandboxed environments and is anchored by the Biomni-R0 reinforcement learning agent and a proprietary biomedical knowledge graph. It is offered alongside an open-source Biomni community edition and sold to enterprise biopharma, biotech, healthcare systems, and individual researchers via freemium, Pro, Team, and custom Enterprise tiers.
Product overview
Phylo offers a single unified product platform, Biomni Lab, built on its Integrated Biology Environment (IBE) architecture, with an open-source community edition called Biomni available alongside it. Biomni Lab is the hosted, enterprise-grade core platform (SOC 2 Type 2 and ISO 27001 compliant) that orchestrates autonomous AI biology agents across add-on capabilities such as the UK Biobank Skill (500,000-person cohort analysis) and agent-managed sandboxes (isolated compute for executing analyses), plus integrations with NVIDIA BioNeMo, Boltz, GeneCards, and Biohub models (ESMC-6B, ESMFold2). The open-source Biomni release serves as the community counterpart to the hosted Biomni Lab, together comprising Phylo's Integrated Biology Environment portfolio for AI-driven biomedical research.
Differentiator
Problem solved
Functional benefit
Brands
- Biomni Lab: Biomni Lab is the first Integrated Biology Environment (IBE), a unified AI-native workspace where biologists orchestrate AI agents across 300+ databases, software systems, and analytical tools to design experiments, analyze data, and accelerate biomedical research.
- Biomni (open-source project)
Products and services
- Biomni Lab
- Biomni (open source)
Quantifiable outcome
- Compresses weeks-long biomedical workflows down to hours (Ginkgo Bioworks case study: 10+ cell-painting and transcriptomic analyses)
- +5 more outcomes
Companies that use Phylo
Customer profileNamed customers3 records
Segments5 records
Ideal customer profiles4 records
Phylo technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- Yes
- API docs
- API detail
Core technology
AI maturity
App detail
Integration12 records
AI capability12 records
Feature8 records
Phylo partnerships and signals
Strategic signalPartnerships
15 partnerships are on record, tiered flagship infrastructure partner, core model partner, flagship enterprise gtm partner, research collaborator, data provider partner, flagship case study partner, clinical research partner, foundational / spin-out partner, flagship scientific advisor and scientific advisor.
- NVIDIA (BioNeMo)flagship infrastructure partnerBiomni Lab integrates resources from NVIDIA's BioNeMo open development platform as scientific skills and open models, starting with AlphaFold Database structures, synthetic protein scaffold datasets, and models including RNAPro, CodonFM, La-Proteina, GenMol, ReaSyn, and OpenFold 3. Users connect via NVIDIA NIM API keys.
- Boltzcore model partnerBiomni Lab integrates Boltz-2 (structure and affinity prediction) and BoltzGen (de novo binder design) via user-provided API keys in Settings → Integrations → Boltz. Enables folding, scoring, and design of protein, peptide, antibody, and nanobody binders, plus virtual screening and synthesizable small-molecule generation.
- Biohub (Chan Zuckerberg Biohub)core model partnerBiohub's latest protein models (ESMC-6B and ESMFold2) are deployed on Biomni Lab's HPC cluster and accessible directly from chat without setup or GPU provisioning, enabling residue-level embeddings, zero-shot variant effect prediction, and structure prediction.
- ZSflagship enterprise gtm partnerZS (15,000+ employee management consulting and technology firm) partnered with Phylo to bring agentic AI into enterprise R&D. Together they deploy Biomni Lab for bioinformatics pipelines, literature reasoning, molecule/protocol design, hypothesis generation, and bio foundation model fine-tuning, supported by ZS's research strategy, data integration, governance, and enterprise adoption expertise.
- Manuel Rivas (Stanford Biomedical Data Science)research collaboratorCo-developed the Genetic Target Hypothesis Biomni skill with Prof. Manuel Rivas at Stanford Biomedical Data Science, which transforms UK Biobank rare-variant burden statistics into ranked therapeutic target hypotheses in minutes.
- GeneCardsdata provider partnerBiomni Lab integrates GeneCards to ground biomedical agentic queries in a comprehensive biomedical knowledge base.
- Ginkgo Bioworksflagship case study partnerJoint case study validating Biomni Lab in a real production environment. Ginkgo's Datapoints team used Biomni Lab to accelerate over 10 complex cell-painting and transcriptomic analyses, compressing weeks-long workflows into hours and producing publication-quality results validated by Ginkgo scientists. Quoted by Ayla Ergun, Senior Director of Data Science at Ginkgo Bioworks.
- Consensusdata provider partnerConsensus is integrated as a licensed data source for large-scale academic literature access inside Biomni Lab.
- COSMICdata provider partnerCOSMIC is integrated as a licensed data source for cancer genomics data inside Biomni Lab.
- Addgenedata provider partnerAddgene is integrated as a licensed data source for plasmid discovery inside Biomni Lab.
- Mount Sinaiclinical research partnerPhylo published a case study with Mount Sinai on scaling agentic clinical trial emulation using real-world EHR data, demonstrating Biomni Lab's use for clinical and translational research. Ben Glicksberg (Phylo Founding Advisor) is affiliated with the Icahn School of Medicine at Mount Sinai.
- Stanford University (Stanford AI Lab)foundational / spin-out partnerPhylo spun out of the Biomni open-source research project at Stanford AI Lab, which the founding team started in June 2024. The company maintains the Biomni open-source project and continues collaborations with academic groups at Stanford, including a co-developed Genetic Target Hypothesis skill with Prof. Manuel Rivas at Stanford Biomedical Data Science.
- Carolyn Bertozzi (Scientific Advisor)flagship scientific advisorNobel Laureate Carolyn Bertozzi, leading figure in biochemistry, joined Phylo as a scientific advisor to guide scientific direction.
- Feng Zhang (Scientific Advisor)flagship scientific advisorCRISPR pioneer Feng Zhang, leading figure in genomics, joined Phylo as a scientific advisor.
- Fabian Theis (Scientific Advisor)scientific advisorFabian Theis, leading figure in computational biology (TUM, Helmholtz Munich), joined Phylo as a scientific advisor and provided a public endorsement of Biomni's vision.
Scale indicators13 records
Recent moves7 records
Expansion highlights6 records
Phylo competitors and assessment
Company assessmentEmerging players
- Profluent Bio: Profluent Bio develops AI foundation models for protein design and engineering. It is comparable to Phylo because both push bio-AI foundation models into biotech R&D, though Profluent is a model-first company while Phylo is a platform/orchestration layer that integrates Profluent-adjacent capabilities.
- Cradle: Cradle provides AI-powered protein design tooling for biotech R&D teams. It is comparable to Phylo because it sits inside the same AI-for-biology stack (and competes with Phylo's Boltz/ESMC integrations), but focuses narrowly on protein engineering rather than spanning the full research workflow.
- EvolutionaryScale: EvolutionaryScale develops large-scale biological foundation models (e.g., Evo) for genomics and protein design. It is comparable to Phylo as a bio-AI ecosystem player, but operates at the model layer (which Phylo integrates via Boltz, BioNeMo and OpenFold-style models) rather than as a research workspace.
Broad incumbents
- Dotmatics: Dotmatics (part of Siemens-owned Dotmatics/GraphPad) is a life sciences R&D platform spanning ELN, data management and analytics for pharma/biotech. It is comparable to Phylo as a horizontal research platform for biologists, but lacks the agentic multi-agent architecture that defines Biomni Lab.
- Schrödinger: Schrödinger provides computational chemistry and materials simulation software widely used in pharma R&D. It is comparable to Phylo as an established incumbent selling AI/ML tooling into biopharma research, but operates at the molecular simulation layer rather than orchestrating the broader research workflow.
- Recursion: Recursion is a publicly listed AI-driven drug discovery company combining high-throughput wet-lab experimentation with ML. It is comparable to Phylo as a broader incumbent in AI-for-biology with established pharma partnerships, though it is far larger and more vertically integrated into its own pipeline.
Direct peers
- FutureHouse: FutureHouse builds AI 'crow' agents (e.g., Robin, Falcon) that automate scientific literature review and reasoning tasks. It is comparable to Phylo's Biomni Lab because both deploy multi-agent systems to execute biomedical research workflows end-to-end, though FutureHouse is more literature- and reasoning-focused while Phylo spans wet-lab execution.
- Benchling: Benchling is the leading cloud R&D platform for biologists, offering notebooks, registry, inventory and assay workflows plus an emerging AI/agent layer. It is the closest direct peer to Phylo's Biomni Lab because both target biomedical research teams with a unified software environment, but Benchling is more focused on lab data management while Phylo leans agentic and tool-orchestration.
- Lila Sciences: Lila Sciences is building an 'AI science factory' that combines autonomous labs with foundation models for scientific discovery. It is directly comparable to Phylo because both pursue agentic AI for biology at scale with significant capital backing and a similar narrative of compressing research timelines.
- Insitro: Insitro combines ML/AI with high-throughput biology for drug discovery. It is comparable to Phylo because both serve biopharma R&D with AI-augmented biology workflows, though Insitro is more vertically integrated into proprietary drug programs while Phylo sells a horizontal research platform.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Phylo social profiles
Digital presencePhylo compliance and trust
Trust signalCompliance2 records
Phylo financial estimates
Financial estimateRevenue estimate
Valuation estimate
Phylo leadership team
Management profileNumber of profiles
Profiles10 records
Phylo funding detail
Funding detailFunding overview
Funding rounds1 record
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Phylo M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Phylo
What does Phylo do?
Phylo provides Biomni Lab, the first Integrated Biology Environment (IBE) — a unified cloud workspace where biologists collaborate with multi-agent AI to plan, execute, and review biomedical research end-to-end. The platform orchestrates 300+ biomedical databases, software systems, and analytical tools within sandboxed environments and is anchored by the Biomni-R0 reinforcement learning agent and a proprietary biomedical knowledge graph. It is offered alongside an open-source Biomni community edition and sold to enterprise biopharma, biotech, healthcare systems, and individual researchers via freemium, Pro, Team, and custom Enterprise tiers.
Is Phylo a public or private company?
Phylo is a private company. It is classified as venture growth investor backed and is currently operating.
When was Phylo founded?
Phylo was founded in 2026. It employs 1 to 10 people.
Where is Phylo based?
Phylo is headquartered in South San Francisco, United States, in the North America region.
How does Phylo make money?
Five revenue lines are on record. Free / Individual Tier is the primary driver. The others are pro Subscription, team Subscription, enterprise Contracts and licensed Materials & Data Monetization (partnership/embedded fees).
Who are Phylo's main competitors?
Emerging players on record are Profluent Bio, Cradle and EvolutionaryScale. Broad incumbents are Dotmatics, Schrödinger and Recursion. Direct peers are FutureHouse, Benchling, Lila Sciences and Insitro.
Does Phylo have an API?
Yes. Phylo's Biomni Lab platform exposes API-based integrations for third-party AI models and data sources. Users configure API keys in Settings → Integrations to connect providers such as NVIDIA BioNeMo (NIM) and Boltz. The Terms of Service reference an applicable application programming interface ('API') governing programmatic access to Biomni Lab. No public REST/GraphQL endpoints, rate limits, versioning, or developer portal details are publicly documented.
What industry is Phylo in?
Phylo's product category is AI Biomedical Research Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAGAJAC, Scientific Data Management & Data Platforms (SDMS/Data Lakehouse for R&D). Its NAICS code is 513210 and its SIC code is 7372.